Abstract 4820: Anti-CD72 nanobody-based CAR-T affinity maturation leads to improved in vitro efficacy versus low antigen density lymphoma models, but limited benefit in vivo.

Adila Izgutdina, Tasfia Rashid, Bonell Patino-Escobar, Sujata Walunj, Huimin Geng, Amrik Kang, Szu-Ying Chen, Haley Johnson, William C. Temple, Matthew A. Nix, Akul Naik, Emilio Ramos, Hiroyuki Takamatsu, Daniel Gil-Alós, Joaquin Martinez-Lopez, Antonio Valeri, Constance Yuan, Hao-Wei Wang, Sarah Aminov, Srabani Sahu, Christopher Carpenter, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Isa Tariq, Veronica Steri, Samir Parekh, Amit Verma, Nirali N. Shah, Arun P. Wiita. Abstract 4820: Anti-CD72 nanobody-based CAR-T affinity maturation leads to improved in vitro efficacy versus low antigen density lymphoma models, but limited benefit in vivo. Cancer Research. 2025 Apr 21; 85(8_Supplement_1):4820-4820.